Zymergen

Zymergen is a biotechnology company that specializes in the fields of machine learning, big data, and artificial intelligence. The company partner with nature to create materials and products across industries from agriculture to electronics, consumer care to pharmaceuticals, and more.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AutoZone

Lordstown Motors

As if to underscore the shrinking number of earnings reports now trickling rather than pouring out of U.S.

Earnings Previews: AutoZone, Lordstown Motors, Zymergen

EMERYVILLE, Calif., May 21, 2021 (GLOBE NEWSWIRE) -- Biofacturing leader Zymergen today announced the company will be participating in the upcoming UBS Global Healthcare Virtual Conference.

Zymergen to Present at UBS Global Healthcare Virtual Conference

Less than a month ago, Zymergen Inc. (NASDAQ: ZY) came public, raising $500 million in an upsized traditional IPO.

What These 4 Top Analysts Love About Hot Biofacturing Firm Zymergen

EMERYVILLE, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Biofacturing leader Zymergen, today announced it will report financial results for the first quarter 2021 after market close on Monday, May 24th, 2021. The company's management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.

Zymergen to Report First Quarter 2021 Financial Results on May 24, 2021

Calyxt

Thermo Fisher Scientific

Here's what to look for and what to steer clear of.

2 Risky Life-Sciences Stocks to Avoid and 1 to Buy Now

The synthetic biology upstart will have enough cash to hit the ground running.

This Is Why Zymergen's IPO Was a Huge Success

EMERYVILLE, Calif., April 26, 2021 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen”), one of the world's foremost biofacturing companies, today announced the closing of its initial public offering of 18,549,500 shares of its common stock, including the full exercise by the underwriters of their option to purchase 2,419,500 additional shares of common stock, at a public offering price of $31.00 per share. The shares are listed on the Nasdaq Global Select Market under the ticker symbol “ZY”.  The gross proceeds from the offering to Zymergen, before deducting underwriting discounts and commissions and other offering expenses payable by Zymergen, are approximately $575 million.

Zymergen Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Zymergen's technology seeks to displace petrochemicals that are polluting the planet.

Zymergen Rises 21% in Market Debut

Zymergen Inc. received a nice reception on Wall Street in its public debut, as the stock opened 30% above its initial public offering price. The "biofacturing" company said overnight that its upsized IPO priced at $31 a share, at the top of the expected range of between $28 and $31 a share.

Zymergen's stock opens up 30%, then pares some gains

"I love the symbolism that we're going public on Earth Day," says Zymergen's Josh Hoffman. The synthetic biology company raised $500 million in an IPO set to value the company at more than $3 billion.

In An Earth Day Test For Synthetic Biology Field, Zymergen Raises $500 Million In IPO

Zymergen Inc. is set to go public Thursday, after the biofacturing company's upsized initial public offering priced at $31 a share, at the top of the expected range. The company sold 16.13 million shares in the IPO, up from previous expectations of 13.6 million shares, to raise $500.0 million.

Zymergen's upsized IPO prices at top of expected range, valuing 'biofacturing' company at $3 billion

EMERYVILLE, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen”), one of the world's foremost biofacturing companies, today announced the pricing of its initial public offering of 16,130,000 shares of its common stock at a public offering price of $31.00 per share. In addition, Zymergen has granted the underwriters a 30-day option to purchase up to an additional 2,419,500 shares of its common stock at the initial public offering price, less underwriting discounts and commissions. Zymergen's common stock is expected to begin trading on the Nasdaq Global Select Market on April 22, 2021 under the ticker symbol “ZY”. The gross proceeds from the offering to Zymergen, before deducting underwriting discounts and commissions and other offering expenses payable by Zymergen, are expected to be approximately $500 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on April 26, 2021, subject to the satisfaction of customary closing conditions.

Zymergen Announces Pricing of Upsized Initial Public Offering

NeuroPace

UiPath

SkyWater Technology

Latham Group

There have been quite a few appealing Initial Public Offerings (IPOs) available on the market so far this year. Here are some upcoming IPOs that investors should be watching out for.

Let's Take a Look At Some Upcoming IPOs This Week

DoubleVerify Holdings

KnowBe4

Agiliti Inc

This week's offerings don't have quite the same high profile as last week's highly anticipated IPO of Coinbase Global (NASDAQ: COIN). Nevertheless, there are several exciting IPOs that investors should consider this week, including UiPath and Latham Holdings.

IPO Preview: UiPath Inc, KnowBe4, Zymergen, Latham Holdings Highlight Busy Week Of Offerings

News for Zymergen Stock (ZY)